We report a case of obvious pseudoaldosteronism which occurred after the additional administration of cilostazol against arteriosclerosis obliterans (ASO) 
Introduction
Licorice-induced pseudoaldosteronism is one of the well known adverse reactions in the patients receiving licorice and its more purified product, glycyrrhizin, which involves the following steps; glycyrrhizin and its metabolites inhibit the activity of 11β-hydroxysteroid dehydrogenase type 2 (11 βHSD2) which converts cortisol to corticosterone, potentiate the binding capacity of cortisol to the mineral corticoid receptor, and consequently activate the down-stream system of the mineral corticoid receptor. As a final result, activation of sodium-reabsorption and inhibition of potassiumreabsorption cause hypertension, metabolic alkalosis, and hypokalemia (1) (2) (3) . However, the precise metabolic pathway of orally administered glycyrrhizin and their key metabolic substances to inhibit 11β activity are still controversial (3) . Here, we report a case of psuedoaldosteronism, which had been manifested exclusively after additional administration of cilostazol, a type III phosphodiesterase inhibitor, to glycyrrhizin; it was not induced by glycyrrhizin alone.
T a b l e 1 . L a b o r a t o r y F i n d i n g s
T h e v a l u e s o f C B C a n d B C a r e d e r i v e d f r o m t h e d a t a o b t a i n e d i n t h e f i r s t we e k o f J u n e , a n d o t h e r v a l u e s o f e x a mi n a t i o n s a r e s h o wn wi t h t h e d a t e o b t a i n e d . T T KG: T r a n s t u b u l a r K + c o n c e n t r a t i o n g r a d i e n t . 
Discussion
The patient reported here was a case of pseudoaldosteronism caused by the combined administration of glycyrrhizin and cilostazol, not by glycyrrhizin alone, which had never been reported before. The interaction of glycyrrhizin with other drugs was restricted to a few agents; mostly steroids (1) . As summarized in Fig. 2 
, orally administered glycyrrhizin was metabolized to glycyrrheic acid or 3β-monoglucuronyl glycyrrhetic acid (3MGA) by glucuronidase produced by bacterial flora in the intestine before absorption of the drug. After absorption, these two metabolites of glycyrrhizin primarily adhere to serum albumin in the portal circulation (4, 5). It is known that the binding of glycyrrhizin to albumin is competitive with the Ca-channel blockers; diltiazem, verapamil, and nifedipine (6). Nifedipine had been prescribed for the patient from 2001; it may reduce the binding capacity of albumin to glycyrrhizin, but it is insufficient to induce pseudoaldosteronism. Some glycyrrhetic acid metabolites conjugate with glucuronic acid again in the liver to be excreted in the bile, and the rest enters general circulation to exert their action. Regarding the metabolites of glycyrrhizin, only MGA inhibits 11β HSD2 activity, not glycyrrhetic acid or the other metabolites (7). Licorice which is the raw material of glycyrrhizin had never prescribed in the present case; it has an inhibitory effect on cytochrome P 450 (CYP) 3A4, but the similar inhibitory effect of glycyr-
rhizin on CYP 3A4 was denied (8) .
As Fig. 3 shows, cilostazol is rapidly absorbed in the intestine, then it binds serum albumin, and undergoes hydration reaction to produce OPC-13015, OPC-13213, and other metabolites by CYP3A4, CYP2D6, and CYP2C19 in the liver. Cilostazol and these compounds are finally excreted in the stool (60%) and in the urine (40%) (9 
d i n t h e i n t e s t i n e . T h e n i t i s t r a n s f e r r e d t o t h e l i v e r a n d i s h y d r a t e d b y c y t o c h r o me P 4 5 0 ( CYP 3 A4 , CYP 2 D6 , a n d CYP 2 C1 9 ) . T h e me t a b o l i t e s a r e e x c r e t e d i n t h e b i l e ( 6 0 %) a n d i n t h e u r i n e ( 4 0 %) .
direct effect of cilostazol which increases the intracellular cyclic AMP concentration through inhibiting phosphodiesterase IIIa activity in cardiac muscular cells. Actually, palpitation is reported to be one of the well known adverse reactions of cilostazol (10) . The free cilostazol concentration in the serum may also be elevated by due to reduced binding opportunity to serum albumin in the competition with glycyrrhizin.
